Project Grant R44HD107766
- Federal Project Grant Award Summary On September 10, 2025, the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded Syntis Bio Inc. $343,635 under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to advance development of SYNT-213, an innovative once-daily oral therapeutic for Maple Syrup Urine Disease (MSUD). The project deliverables include optimization and development of a solid dosage form combining a proprietary...
- Federal Project Grant Award Summary Massachusetts General Hospital (MGH), a Harvard Medical School-affiliated academic medical center, received a $201,000 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) effective August 1, 2025, through July 31, 2027. This R03 award supports a discrete, well-defined research project that expands upon a parent...
- Project Grant Award Summary The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded the University of Pennsylvania a $3.23 million Project Grant on September 15, 2025, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate mitochondrial dysfunction mechanisms in myelodysplastic syndrome (MDS) driven by splicing factor mutations. The research project, which extends through August 31, 2029, focuses on...
- Federal Project Grant Award Summary Icahn School of Medicine at Mount Sinai received a $361,250 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), effective July 1, 2025, with completion scheduled for June 30, 2028. The award funds a Phase 2 randomized, placebo-controlled crossover clinical trial investigating atomoxetine, an existing...
- Grant Award Summary New York University School of Medicine received a $847,498 Project Grant awarded on August 20, 2025, from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant funds the development and testing of AIMANAGE, an artificial intelligence-driven clinical decision support system and chatbot designed to improve patient adherence and reduce clinical...
- PREMEDIA Cooperative Agreement Summary Northwestern University received a $2.29 million Cooperative Agreement from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to conduct the Precision Medicine in Achalasia (PREMEDIA) study. Awarded September 18, 2025, with completion targeted for August 31, 2030, this multicenter randomized clinical trial investigates novel approaches...
- Federal Project Grant Award Summary Massachusetts General Hospital received a $123,750 Project Grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), awarded on May 18, 2026, with completion by April 30, 2028. The award funds research to develop molecularly-informed polygenic scores for predicting individual response to omega-3 fatty acid (N3FA) supplementation, with the...
- Federal Project Grant Award Summary The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded the Regents of the University of Michigan a $779,978 Project Grant on September 6, 2025, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). This research initiative addresses critical health disparities in diabetes management by developing and testing adaptive intervention sequences designed to improve outcomes for individuals with...
- Federal Project Grant Award Summary The University of Massachusetts Medical School received a $2.64 million Project Grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), effective September 1, 2025, through August 31, 2029. This award funds biomedical research investigating novel mitochondrial mechanisms underlying obesity pathogenesis, with specific focus on...
- Federal Project Grant Award Summary Aurora Health Care, Inc. received a Project Grant award of $762,556 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), effective September 15, 2025, with completion targeted for June 30, 2030. The award funds development of a novel, semi-automated self-monitoring feedback system designed to enhance weight loss interventions in...
MYRAREDIET: A DIET TRACKING, MONITORING AND OPTIMIZATION MHEALTH SOLUTION FOR PATIENTS WITH INBORN ERRORS OF METABOLISM - PROJECT ABSTRACT INBORN ERRORS OF METABOLISM (IEM) ARE A GROUP OF RARE GENETIC (INHERITED) DISORDERS THAT CAUSE A BLOCK IN A METABOLIC PATHWAY LEADING TO CLINICALLY SIGNIFICANT CONSEQUENCES, CAUSING DEVELOPMENTAL AND INTELLECTUAL DISABILITIES, SEIZURES, AND, IF UNTREATED, COMA AND DEATH. THE MAJORITY OF THE IEM DISORDERS ARE MANAGED BY MANIPULATION AND MODIFICATION OF DIET ALONE TO REDUCE TOXIC METABOLITES, OR WITH A COMBINATION OF DIETARY MODIFICATION AND MEDICATIONS. THE COMPLEX DIETARY THERAPIES USED IN IEM CHALLENGE ROUTINE DIETARY RECOMMENDATIONS AND RENDER DIET APPS DESIGNED FOR THE GENERAL PUBLIC OF LITTLE UTILITY IN THESE CONDITIONS. ALSO, NO DIET APP IS DEVELOPED SPECIFICALLY FOR THE IEM COMMUNITY AND MEETS THE RIGOR REQUIRED FOR RESEARCH, PARTICULARLY THE NEED TO MEASURE SPECIFIC AND MULTIPLE AMINO ACID CONTENT IN THE DIET TO FACILITATE MORE STUDY ON IMPACT ON BRAIN NEUROCHEMISTRY. WITHIN THE FIELD OF IEM, PAPER DIET DIARIES ARE UTILIZED TO MONITOR FOOD INTAKE. THESE DIARIES ARE FREQUENTLY INADEQUATE IN CAPTURING WHAT IS ACTUALLY BEING CONSUMED DUE TO RECALL ERRORS AND OTHER FACTORS. NOVEL METHODS OF ASSESSING DIETARY INTAKE ARE REQUIRED TO REDUCE THE DIET TRACKING BURDEN, IMPROVE ACCURACY IN DIETARY SURVEYS, AND IMPROVE DIET ADHERENCE. WE PROPOSE TO DEVELOP AND VALIDATE MYRAREDIET (MRD) TO ADDRESS AN UNMET NEED IN THE IEM POPULATION TO ASSIST WITH DIETARY MANAGEMENT DESIGNED TO INCREASE ADHERENCE AND COMPLIANCE THAT COULD LEAD TO IMPROVED OUTCOMES, WHILE FACILITATING THE COLLECTION OF DIETARY DATA FROM INDIVIDUALS WITH IEM FOR RESEARCH PURPOSES. MRD INCLUDES A PATIENT PORTAL, A CLINICAL DIETICIAN PORTAL, AND A RESEARCHER PORTAL. THE PATIENT PORTAL IS TO HELP IEM PATIENTS TRACK AND MONITOR THEIR OWN DIET SO THEY CAN MEET THEIR STRICT DIET TARGETS AND RESTRICTIONS. THE CLINICAL DIETICIAN PORTAL IS TO HELP CLINICAL DIETICIANS MANAGE DIET MODIFICATIONS FOR INDIVIDUALS WITH IEM. THE RESEARCHER PORTAL IS TO FACILITATE THE CONDUCT OF DIET-BASED STUDIES AND THE ANALYSIS OF STUDY RESULTS. THE AIMS FOR PHASE II ARE: 1) ENHANCE AND REFINE THE PHASE I MRD PROTOTYPE BY ADDING FEATURES TO IMPROVE DIET REPORTING ACCURACY AND REDUCE USER BURDEN; 2) CONDUCT A CRITERION VALIDITY STUDY TO TEST THE AGREEMENT BETWEEN MRD AND A WIDELY USED AND VALIDATED INTERVIEW-BASED 24-HOUR RECALL METHOD; AND 3) CONDUCT A RANDOMIZED CONTROLLED TRIAL TO ASSESS THE EFFECTS OF USING MRD ON PARTICIPANTS' DIET TRACKING AND MONITORING BEHAVIORS. OUR HYPOTHESES ARE THAT COMPARED TO PAPER DIET DIARIES, THE USE OF MRD WILL RESULT IN 1) HIGHER SATISFACTION WITH GREATER ADHERENCE TO SELF-REPORTING OF DIETARY INTAKE; AND 2) PROTEIN CONSUMPTION MORE CLOSELY ALIGNED TO PROTEIN RESTRICTION TARGET.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $0 | 3/4/26 | ||
| Not listed | $795.7k | 8/20/23 | ||
| Not listed | $0 | 11/4/22 | ||
| Not listed | $0 | 11/4/22 | ||
| Not listed | $0 | 11/4/22 |